Publications
5808 Results
- Journal / Conference
- Journal of Clinical Oncology Vol 29, No 15_suppl (May 20 Supplement), 2011: abst. 8505; ASCO Annual Meeting ((June 4-8, 2011, Chicago, IL), oral;
- Year
- 2011
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1697
Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate and high-risk melanoma (Intergroup trial E 1697)
- Journal / Conference
- American Journal of Clinical Oncology, Apr; 33(2):117-120;
- Year
- 2010
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID19770625
- PMC
- PMC2967385
- Study Number(s)
- SWOG-9511
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
- Journal / Conference
- Head and Neck, Feb; 32(2):221-228;
- Year
- 2010
- Research Committee(s)
- Head and Neck
- Study Number(s)
- S0216
Docetaxel, cisplatin and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) [PMID: 19557750;PMC2967367]
- Journal / Conference
- Lancet Oncology 11:55-65
- Year
- 2010
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [PMID20005174; PMC3058239]
- Journal / Conference
- Clinical Trials 7(1):90-99
- Year
- 2010
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
Impact of supplemental site grants to increase African American accrual for SELECT. PMID: 20156960
- Journal / Conference
- British Journal of Urology International 105(3):317-321;
- Year
- 2010
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0031
Results of Southwest Oncology Group phase II evaluation (study S0031) of ZD 1839 for advanced transitional cell carcinoma of the urothelium [PMID19888985]
- Journal / Conference
- Cancer 116(2):424-431; online 11/13/09;
- Year
- 2010
- Research Committee(s)
- Melanoma
- PMID
- PMID19918923
- PMC
- PMC2811758
- Study Number(s)
- S0508
Phase II trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
- Journal / Conference
- Annals of Oncology 21(6):1196-1202;
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8809, S9800, S9911
Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]
- Journal / Conference
- American Journal of Clinical Oncology, Oct; 33(5):495-499;
- Year
- 2010
- Research Committee(s)
- Melanoma
- PMID
- PMID20019577
- PMC
- PMC2978644
- Study Number(s)
- S0331
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331)
- Journal / Conference
- Journal of Clinical Oncology 28(7):1247-1253;
- Year
- 2010
- Research Committee(s)
- Sarcoma
- Study Number(s)
- S0033